Biodexa Pharmaceuticals PLC has announced a significant advancement in its clinical research efforts with the imminent initiation of the Phase 3 study for its drug eRapa, targeting familial adenomatous polyposis (FAP). The double-blind, placebo-controlled trial will involve 168 patients, randomized in a 2:1 ratio of drug to placebo. The study is set to be conducted across approximately 30 clinical sites in the United States and Europe, with recruitment expected to commence in the upcoming weeks. The US segment of the study will be coordinated by LumaBridge in San Antonio, Texas, while Precision for Medicine LLC will oversee the European component. Biodexa has secured substantial funding for the eRapa Phase 3 program through a CPRIT grant and company contributions, ensuring financial resources are in place to support the trial's execution.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.